SVV 005
Alternative Names: SVV-005Latest Information Update: 22 Sep 2023
At a glance
- Originator Seneca Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 21 Aug 2023 Preclinical trials in Solid tumours in USA (IV) (Seneca Therapeutics pipeline, August 2023)